CORDIS · 898858 · H2020
Met4Bone Metabolites as immunomodulatory additives for biomaterials
Coordinator: RIGAS TEHNISKA UNIVERSITATE (LV)
The biomaterials are crucial for the surgical remediation of bone defects caused by various diseases e.g. osteoporosis and traumatic fractures. However, there are several risks associated with this treatment; first, the surgical procedure itself carries a potential risk of inflammation and bone infection, second, the bone replacement can fail requiring revision surgery. In fact, the host immune response to implanted materials and devices is the main factor that will determine a long-term functional outcome of the biomaterial mediated treatment. Therefore, the bone biomaterial ability to modul…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
The project runs over approximately 2 years from 2020-08-01 to 2022-07-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from LV
see all →- VIOBOND — VIOBOND – sustainable binder: Upscaling new lignin-phenol-formaldehyde resin production with wood-based biorefinery lignin101022987 · H2020 · €15.9M
- PMPC — Centre of Excellence for Precision Medicine in Pediatric Care101136530 · HORIZON · €14.4M
- INNOVABALT — Strengthening the research and innovation capacities of the Latvian Institute of Organic Synthesis, the leading Baltic regional centre for drug discovery316149 · FP7 · €4.7M
- CIRCLEUP — 100 Households, 100 Circular Stories: Inspiring Sustainable Living in Europe101135495 · HORIZON · €4.6M
- FOTONIKA- LV — Unlocking and Boosting Research Potential for Photonics in Latvia – Towards Effective Integration in the European Research Area285912 · FP7 · €3.8M
- BioMagnetLink — Biological magnets as a unifying link to multidisciplinary research excellence101187789 · HORIZON · €2.6M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the MSCA-IF-EF-ST funding scheme.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-MSCA-IF-2019.
- Who coordinates the project?
- The project is coordinated by RIGAS TEHNISKA UNIVERSITATE (LV).
- What is the project timeline?
- The project runs from 2020-08-01 to 2022-07-31 — approximately 2 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 898858.